Replies to post #42344 on Biotech Values

[DewDiligence]

> DYAX – which do you think is correct regarding DX-88 in CTS?
1. GENZ did not/does not want to pursue this indication.
2. DYAX did not want to give up rights to DX-88 for CTS.<

DYAX bought out GENZ’s 50% stake of DX-88 for the CTS indication in 2003, according to an option clause in the original JV. For the right price, they probably would have let GENZ back in now.